Slides
Page 1
DRAFT – v4 Infection Prevention. For Life. INVESTOR PRESENTATION FY26 HALF YEAR RESULTS 24 February 2026 Michael Kavanagh CEO and President Jason Burriss CFO For personal use only
Page 2
Nanosonics Limited | FY26 Half Year Results | 2 Protecting millions of patients every year TROPHON Market leadership in ultrasound probe reprocessing CORIS Phased commercialisation underway Nanosonics develops transformative technologies in medical device reprocessing to improve patient safety and deliver better health outcomes. 38,080 cumulative installed base1 Opportunity to transform endoscope reprocessing 1. Cumulative sales of new installed base units. For personal use only
Page 3
Nanosonics Limited | FY26 Half Year Results | 3 1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. The average exchange rate used for the Company's major foreign currency (USD) for the half year was 0.6560 (H1 FY25: 0.664). For full details, please see the note on Appendix slide. TOTAL REVENUE $102.2M 9% on PCP GROSS PROFIT MARGIN 76.3% 2% pts on PCP OPERATING EXPENSES $69.5M 4% on PCP CONSOLIDATED PROFIT BEFORE TAX $10.6M 3% on PCP up 8% CC1 FY26 H1 financial highlights up 13% CC1 EBIT $8.4M 3% on PCP OPERATING MARGIN $8.5M 27% on PCP up 15% CC1 Revenue growth and margin expansion drive solid operating performance up 18% CC1 For personal use only
Page 4
Nanosonics Limited | FY26 Half Year Results | 4 Digitalisation Key achievements in H1 FY26 Innovation Operations trophon3® and trophon2® Plus launched CORIS® registrations in Australia, EU and UK achieved New HQ and manufacturing facility secured – Move April 2027 New Executive and leadership talent appointed to lead next phase of growth New ERP implemented & operational Cloud based customer traceability offerings go live. Nanosonics Limited | FY26 Half Year Results | 4 Continuing momentum for long-term growth For personal use only
Page 5
Nanosonics Limited | FY26 Half Year Results | 5 With a critical mass of 38,080 units, the large and growing installed base is driving strong recurring revenue growth through customer value expansion GLOBAL CUMULATIVE INSTALLED BASE (DEVICES)1 Approximately 29 million patients protected annually from the risk of cross contamination 1. Cumulative sales of new installed base units. 6% vs PCP 38,080 devices driving scalable recurring revenue growth 33,550 34,790 35,840 37,000 38,080 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 RECURRING REVENUE ($M) 9% vs PCP • Core consumables grew 9% on pcp. • Service & repairs grew 24% on pcp. • Ecosystem consumables grew 6% on pcp. • Spare parts declined 23% on pcp, reflecting lower requirements as upgrade sales increase. 38.9 41.5 43.7 48.5 47.8 10.5 13.4 13.1 16.3 16.2 5.4 6.4 7.3 7.8 7.8 2.8 2.7 5.1 4.4 3.9 57.7 64.1 69.2 76.9 75.7 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Spare parts Ecosystem Service Core Consumables For personal use only
Page 6
Nanosonics Limited | FY26 Half Year Results | 6 NEW INSTALLED BASE 1,080 units UPGRADES 990 units 3% on PCP 46% on PCP trophon installations grow 20% on pcp to 2,070 devices Continued growth in the cumulative installed base with record upgrade units in North America CAPITAL REVENUE ($M) 9% vs PCP 21.9 26.3 24.4 28.1 26.5 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Capital revenue growth includes volume-base pricing for several large deals. Upgrade were mainly trophon2 devices, as trophon3 was launched midway through the half, and customer budgets for trophon2 were well progressed. These trophon2 upgrade customers now have option to further upgrade with trophon 2 Plus software. For personal use only
Page 7
FY26 half year results For personal use only
Page 8
Nanosonics Limited | FY26 Half Year Results | 8 Driving value creation Trusted brand in automated high level disinfection with 38,080 cumulative installed base Customer value expansion powering high margin recurring revenue. Disciplined capital allocation driving operating leverage. Strong cash balance and high return on capital on trophon only business creates opportunities for future growth and shareholder returns. • Continued investment in product expansion • CORIS commercialisation • Market expansion • Share buy back Nanosonics Limited | Full Year Results 2025 | 8 For personal use only
Page 9
Nanosonics Limited | FY26 Half Year Results | 9 Total revenue up 9% to $102 million Installed base expansion and record US upgrades support capital and recurring revenue performance Recurring revenue from consumables & service up 9% on pcp to $75.7 million. • Core consumables grew 9% on pcp • Service & repairs grew 24% on pcp • Ecosystem consumables grew 6% on pcp • Spare parts declined 23% on pcp, reflecting lower requirements as upgrade sales increase. Capital revenue up 9% on pcp to $26.5 million • Capital revenue growth includes volume-base pricing for several large deals. TOTAL REVENUE ($M) 21.9 26.3 24.4 28.1 26.5 57.7 64.1 69.2 76.9 75.7 79.6 90.4 93.6 105.0 102.2 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Capital Recurring 9% vs PCP For personal use only
Page 10
Nanosonics Limited | FY26 Half Year Results | 10 Regional performance: North America REVENUE ($M) Graphs are not to scale and therefore not comparable. 10% vs PCP 20.4 24.6 22.7 26.7 25.5 51.9 57.3 62.0 69.0 67.7 72.3 81.9 84.7 95.7 93.2 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Capital Recurring 480 820 610 890 980 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 Continued revenue growth, up 10% on pcp 61% on pcp UPGRADES (devices) North America achieves double digit revenue growth and record upgrade activity CUMULATIVE INSTALLED BASE (devices) Continued growth in new IB, 890 units added in H1. Record half for upgrades, with 980 units added. 6% on pcp 29,360 30,390 31,330 32,310 33,200 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 For personal use only
Page 11
Nanosonics Limited | FY26 Half Year Results | 11 Regional performance: EMEA & APAC Graphs are not to scale and therefore not comparable. 0.7 1.0 1.2 0.8 0.6 3.5 4.7 4.7 5.5 5.7 4.3 5.8 5.9 6.3 6.3 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Capital Recurring REVENUE ($M)INSTALLATIONS (devices) 7% vs PCP Focus on new installed base and recurring revenue opportunity, as majority of first generation trophon EPR upgrade opportunity is complete EUROPE, UK AND MIDDLE EAST REVENUE ($M)INSTALLATIONS (devices) ASIA PACIFIC • 90 new installed base, up 125% on pcp. • Majority of EPR units already upgraded. 0.8 0.7 0.5 0.6 0.4 2.2 2.0 2.5 2.4 2.2 3.1 2.7 3.0 3.0 2.6 FY24 H1 FY24 H2 FY25 H1 FY25 H2 FY26 H1 Capital Recurring • Recurring revenue growth of 22% on pcp. • Capital revenue reduction, includes UK MES purchase model with no upfront capital component. • 100 new installed base, up 43%. • Majority of original trophon EPR units are already upgraded. • Recurring revenue moderation of 11% on pcp, impacted by distributor stocking levels and activity. 70 10 50 30 0 80 140 70 130 100 150 150 120 160 100 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 Upgrades New IB 70 60 20 60 10 50 70 40 50 90 120 130 60 110 100 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 Upgrades New IB 43% on pcp 17% on pcp New installed base Total Installations 13% vs PCP 67% on pcp New installed base Total Installations 125% on pcp For personal use only
Page 12
Nanosonics Limited | FY26 Half Year Results | 12 Profit & Loss • Total revenue growth of 9% to $102.2 million (8% in cc) • Gross profit margin of 76.3%, down 2.2% on pcp, driven by tariffs, airfreight and product mix. • Operating expenses of $69.5 million, up 4% on pcp • R&D as a percentage of sales reduced from 18% in H1 FY25 to 15% in H1 FY26. • Operating margin expansion to $8.5 million, 27% growth on pcp (up 18% at cc). • Other gains/(losses) of ($0.7) million compared to gain of $1.3 million in pcp driven by unrealised FX losses. • EBIT of $8.4 million, down 3% on pcp (up 15% in cc). • Profit before tax of $10.6 million, down 3% on pcp (up 13% in cc). Operating margin of $8.5 million, up 27% $ millions H1 FY26 H1 FY25 Change % Change % at CC Capital revenue 26.5 24.4 9% Consumable/service revenue 75.7 69.2 9% Total revenue 102.2 93.6 9% 8% Gross profit margin 78.0 73.4 6% Gross profit margin % 76.3% 78.5% Operating expenses Selling and general 37.1 34.3 8% Administration 17.0 16.0 6% Research and development 15.4 16.5 -7% Total Operating expenses 69.5 66.7 4% Operating margin 8.5 6.7 27% 18% Other income 0.6 0.6 - Other gains/(losses)-net (0.7) 1.3 nm Earnings before interest and tax 8.4 8.7 -3% 15% Finance income-net 2.2 2.2 - Profit before income tax 10.6 10.9 -3% 13% Profit after income tax 9.6 9.8 -1% nm = not meaningful. For personal use only
Page 13
Nanosonics Limited | FY26 Half Year Results | 13 79.7% Improving operating leverage Revenue growth and cost discipline drive margin expansion OPERATING MARGIN ($M) 2.6 4.2 6.7 10.0 8.5 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 Operating margin increased to $8.5 million up 27% on pcp 27% vs pcp OPERATING EXPENSES ($M) 4% vs pcp 60.8 64.8 66.7 71.9 69.5 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 Operating expense growth reduced to 4% to $69.5 million • trophon opex up 1% vs pcp, driving EBIT expansion. Continued investment in CORIS, up 16% vs pcp. • R&D as a percentage of revenue declined from 18% to 15%. Gross profit margin percentage of 76.3%, 2.2pts lower driven by the impacts of tariffs, air freight and product mix. GROSS PROFIT ($M & %) 6% vs pcp 63.4 69.0 73.4 81.9 78.0 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 76.3% 78.0% 78.5% 76.3% For personal use only
Page 14
Nanosonics Limited | FY26 Half Year Results | 14 Strength and scalability of trophon only business1 $ millions H1 FY26 H1 FY25 Change % Capital revenue 26.5 24.4 9% Consumables and service revenue 75.7 69.2 9% Total revenue 102.2 93.6 9% Gross profit 78.0 73.4 6% Gross profit margin % 76.3% 78.5% Operating expenses Selling, general and administration 47.9 46.3 4% Research and development 4.5 5.8 -22% Total Operating expenses 52.4 52.0 1% Operating Margin 25.6 21.4 20% Operating margin % 25.0% 22.9% Other income 0.6 0.6 - - Other gains/(losses)-net -0.7 1.3 nm Earnings before interest and taxes 25.5 23.4 9% Finance income-net 2.2 2.2 - - Profit before income tax 27.7 25.6 8% PBT as a % of revenue 27.1% 27.3% • Operating Margin $25.6 million for trophon only business, up 20% on pcp. • Operating margin as percentage of sales has grown from 22.9% to 25.0%. • PBT of $27.7 million, up 8% on pcp (14% at CC). • Generating significant cash to fund working capital, CORIS and broader long-term growth strategy. Disciplined investment driving ongoing trophon growth and scalability, resulting in a 20% increase in operating margin 1. The pro forma profit before tax for the trophon business is unaudited and has been prepared by management to reflect total Company results less operating costs associated with new product development and commercialisation for CORIS. Operating costs reflect management allocation estimates where resources are shared between trophon and CORIS development and commercialisation. The pro forma profit and loss statement also includes income received from the Jobs Plus Program. nm = not meaningful. For personal use only
Page 15
Nanosonics Limited | FY26 Half Year Results | 15 Cash flow & cash balance Cash outflow reflects planned working capital investment in CORIS & trophon, commencement of share buy-back and timing of receivables. Debt free balance sheet with $159.8 million of cash & cash equivalents provides flexibility for long- term growth. CASH FLOW -$1.4M CASH BALANCE $159.8M Nanosonics Limited | FY26 Half Year Results | 15 For personal use only
Page 16
Strategic growth in ultrasound reprocessing For personal use only
Page 17
Nanosonics Limited | FY26 Half Year Results | 17 Seven growth drivers of trophon ServiceCore consumables trophon3 - ongoing new installed base growth internationally through deeper penetration into hospitals and the private physician segments. Accelerate upgrade adoption – approximately 9,000 EPR device opportunity for upgrade to new trophon3. Core consumables - Growth in volume driven by cumulative installed base growth, ultrasound procedure growth and greater customer awareness of which procedures require HLD. Ecosystem consumables - Product expansion and broader adoption of ecosystem consumables across total installed base by providing customers with complete reprocessing portfolio. Service contract uptake and PAYG service offerings, protecting customers’ capital equipment. Capital software upgrades Connectivity (SaaS) trophon2 Plus - software upgrade package opportunity for approximately 25,000 trophon2 devices bringing the value of trophon3 to all existing trophon2 customers. Traceability solutions - connectivity subscriptions through trophon3 and trophon2 Plus enabling customer compliance with all traceability requirements. Upgrade capital salesNew installed base device sales Ecosystem consumables 1 2 3 4 5 6 7 For personal use only
Page 18
Nanosonics Limited | FY26 Half Year Results | 18 Initial installation Upgrade Year 1 2 3 6 5 6 7 8 14 CAPITAL New installed base & upgrade device sales CONSUMABLES Core & ecosystem SERVICE & REPAIRS CONNECTIVITY CAPITAL Software upgrades for existing trophon2 Installed Base Lifetime value of trophon Each new installed base device has a lifespan of 7-10 years, followed by upgrade to latest generation, with every device delivering customer value and recurring revenue. Traceability portfolio Software upgrades – trophon2 Plus opportunity For personal use only
Page 19
Transforming endoscope reprocessing For personal use only
Page 20
Nanosonics Limited | FY26 Half Year Results | 20 FY26 FY27 & beyond Europe CMR 1st 510(k) European / UK & ANZ Approvals Capital equipment & US consumables manufacturing scale up Broader commercialisation Controlled Market Release 2 Regulatory Approvals & Expanded Scope Indications Commercial Launch CORIS executing on planned milestones1 CORIS milestones to commercialisation 3rd 510(k)2nd 510(k) Australia CMR USA CMR 1. All new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines. 2. The timing of the CMRs in the table are indicative and subject to a range of factors including regulatory timelines and customer site readiness. 1st 510(k) submitted European, UK & ANZ certification UK CMR starts 1st 510(k) outcome US CMR starts European, UK & Australian commercialisation US commercialisation Nanosonics controlled market release of CORIS involves a strategically limited launch into select user environments before full scale commercialisation. It enables real-world feedback and helps identify and resolve any unexpected issues prior to broader commercialisation. For personal use only
Page 21
Nanosonics Limited | FY26 Half Year Results | 21 Controlled Market Release commences First CORIS system installed under CMR "We are looking forward to the multiple benefits that CORIS can bring, from workflow efficiencies to confidence and assurance we are cleaning the endoscopes to the highest standard possible for patient safety.” Deputy Head of Operations and Decontamination at Nanosonics’ first CMR site. For personal use only
Page 22
Nanosonics Limited | FY26 Half Year Results | 22 Endoscopy: a large and growing market 60 million endoscopy procedures are conducted each year across major markets1 1. References on file; available upon request Growth Rate Procedure Volume (m) +5.4% +7.3% +5.8% +7.0% +6.7% +5.4% +6.7% ENDOSCOPIC PROCEDURE VOLUME GI 45.2 Non-GI 15.3 18.1 20.1 Upper GI Colonoscopy Sigmoidoscopy Enteroscopy ERCP EUS Bronchoscopy Urology ENT Gynaecology 4.6 0.4 1.6 0.4 5.6 5.2 3.6 1.0 EU-5 23.0 60m+ANNUAL ENDOSCOPY PROCEDURE VOLUME U.S.A. Germany U.K France Spain/Italy Canada Australia 33.7 7.5 4.8 5.5 5.2 1.7 2.1 Annual Projected procedure growth rate at 6% per annum. 1 75% of procedures are upper and lower gastrointestinal. Colonoscopes and gastroscopes are most commonly used. For personal use only
Page 23
Manual cleaning remains a challenge 1. Sivek AD, Davis J, Tremoulet P, et al. Am J Infect Control. 2022;50(9):1038-1048. 2. Madureira, R. A. da S. & Oliveira, A. C. de. Endoscopic processing: what are the gaps in clinical practice? Rev. Eletr. Enferm 66550, 1–13 (2021). 3. Ofstead, C. L., Wetzler, H. P.,Snyder, A. K. & Horton, R. A. Endoscope Reprocessing Methods. Gastroenterol Nurs 33, 304–311 (2010). 4. Sivek, A. D. et al. Healthcare worker feedback on duodenoscope reprocessing workflow and ergonomics. Am J Infect Control 50, 1038–1048 (2022). Lengthy process with 55 to 200 steps prone to error and variability Complex internal architecture of endoscopes makes manual cleaning extremely difficult with some channels inaccessible for brushing Often manual cleaning isn’t performed correctly 1 Manual cleaning is physically demanding4 with exposure to hazardous materials • Insufficient manual cleaning was reported in 50% of studies and complete neglect of channel brushing was found in 17% of studies, in a 2021 literature review. 2 • Excessive discomfort is reported in neck, shoulders, back and wrists. Nanosonics Limited | Full Year Results 2025 | 23 • Less than half of endoscopes had all components brushed correctly. 3 Manual cleaning is the longest technician-performed step in the endoscope reprocessing cycle, often taking 15-20 minutes or more to complete. 1 For personal use only
Page 24
Nanosonics Limited | FY26 Half Year Results | 24 Contamination persists and adverse events grow Harmful contamination & biofilm persists despite reprocessing More than 35,000 adverse events in 2024, according to FDA MAUDE database 5 202420232022202120202019 • GI endoscopes and bronchoscopes have been associated with far more outbreaks of infections (>130 outbreaks) than any other reusable medical or surgical device in healthcare.1 • In the largest study of its kind (n=90,311), 19.5% of endoscopes had unsafe levels of bacteria.2 • In a 2024 study, 19.8% of endoscopes were contaminated with microbes from oral or gut origin after reprocessing. Manual cleaning durations of ≤7 minutes were associated with 63% higher chance of contamination. (aOR=1.63, 95% CI: 1.06- 2.49, p=0.02). 3 • A 2021 study showed that biofilm or probable biofilm was found in 100% of gastroscope lumens after just 30 days of clinical use. 4 1. Rutala & Weber Rutala, W. A. & Weber, D. J. Reprocessing semicritical items: Outbreaks and current issues. Am J Infect Control 47, A79-A89 (2019). 2. Pineau, Let al. Endoscope reprocessing: Retrospective analysis of 90,311 samples. Endosc Int Open 2023;11:E247-257 3. van der Ploeg, K., Vos, M., Erler, N., Mason-Slingerland, B., Severin, J., & Bruno, M. (2024). Establishing preconditions for effective duodenoscope reprocessing: An observational cohort study. Gastrointestinal Endoscopy, 99(Suppl 6), AB397. 4. Primo, M. G. B. et al. Infect Control Hosp Epidemiology 43, 174-180 (2021). 5. Analysis of FDA MAUDE database by Ofstead and Associates, January 2025, https://www.linkedin.com/posts/ofstead-%26-associates-inc%2E_here-are-the-q4- numbers-for-2024-fda-posted-activity-7282447741207621632-hG8h?utm_source=share&utm_medium=member_desktop&rcm= For personal use only
Page 25
Nanosonics Limited | FY26 Half Year Results | 25 CORIS addresses the challenges of manual cleaning More efficacious CORIS uses a unique mechanism of action, that removes tough soils & biofilms that form in all the channels, including those that cannot be brushed today. More repeatable and reliable As an automated solution, it controls cleaning to each individual channel and delivers consistent results every time. Safer for staff CORIS minimises manual intervention that causes fatigue and injury, as well as reducing splashes and aerosols by guiding them safely to the drain. More efficient Releases staff from hands-on activities to perform other duties. More compliant Automatically captures compliance-critical traceability information and provides new levels of information about the quality of cleaning. PRECISION PERFORMANCE PROTECTION For personal use only
Page 26
Nanosonics Limited | FY26 Half Year Results | 26 Significant growth opportunity CORIS business model & revenue streams Capital equipment to be installed in endoscope reprocessing centres. Range of capital sales models to be available. Number of daily cycles per machine expected to be a multiple of trophon cycles at a higher price to trophon cycle. High percentage of devices expected to take out annual service and maintenance contracts. Opportunity to establish broad ecosystem consumables offering across value chain for use from bedside to automatic endoscope reprocessor (AER). Capital equipment & accessories Service Consumables Ecosystem consumables 1. Ofstead, C.L., Quick, M.R., Eiland, J.E. and Adams, S.J., 2017.A glimpse at the true cost of reprocessing endoscopes. International Association of Healthcare Central Service Material Management. For personal use only
Page 27
Outlook & Guidance For personal use only
Page 28
Nanosonics Limited | FY26 Half Year Results | 28 FY26 guidance at constant currency1 1. Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. Constant currency, using an AUD/USD exchange rate of 0.65 which is also the effective exchange rate for the FY25 results. Note: All guidance is subject to uncertainty in relation to potential impacts associated with macroeconomic and political uncertainty, as well as potential impacts from increased competitive activity in the USA. TOTAL REVENUE $215m to $223m 8% - 12% growth 75% - 77% $147m to $151m 6% - 9% growth • Continued capital and recurring revenue growth, while spare parts are expected to remain lower as older units are upgraded. • Capital average selling prices (ASP) are expected to be broadly consistent with H1 FY26, assuming a similar mix of trophon3 and trophon2 units and number of large-volume upgrade agreements. • No CORIS revenue while Controlled Market Release is underway. • The guidance assumes tariff rates to remain at H1 levels. • Continued OpEx discipline into H2. • Ongoing investment in CORIS phased commercialisation strategy. GROSS MARGIN OPERATING EXPENSES Reiterating full year guidance Guidance is based on FX rates provided in August 2025 of AUD/USD 0.65. The Company has an ongoing currency hedging program in place. If the Revenue range in the above table were recast using an average exchange rate for USD/AUD of 0.70 for H2 FY26, rather than constant currency, and the hedging pr ogram is taken into account, the Revenue range would be approximately 3% lower. Foreign Currency For personal use only
Page 29
Appendix For personal use only
Page 30
Nanosonics Limited | FY26 Half Year Results | 30 Income tax & constant currency disclosure • Effective income tax for the period was 9.2%. • Deferred tax asset consists of: • $1.3m R&D tax credits carried forward • $17.1m all other timing differences and tax losses • Assessment of probability of recovery (and therefore recognition of related benefit) of unrecognised losses is made on an on-going basis. Currently we have $11.7m unrecognised losses. Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. This is done by (1) converting the current year sales, costs and operating expenses of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year (2) restating foreign currency denominated transactions of the parent entity that is impacted by exchange rate movements at the average rates that were applicable in the prior year and (3) by adjusting for foreign currency gains and losses. The average exchange rate used for the Company's major foreign currency (USD) for the half year was 0.656 (H1 FY25: 0.664). *Constant currency revenue, EBIT and PBT have not been audited or reviewed in accordance with Australian Auditing Standards. Income tax Constant currency comparison $ millions FY26 H1 FY25 H1 Income tax expense 1.0 1.1 Components of Net Deferred Tax Asset 31-Dec-25 30-Jun-25 Tax losses 0.3 0.5 R&D tax credits 1.3 - All other timing differences 16.8 18.4 Total 18.4 18.9 Value of carried forward losses & R&D credits Gross Tax Benefit Effective rate % Losses recognised 1.2 0.3 25.0% R&D credits carried forward 4.4 1.3 30.0% Total losses and R&D credits recognised 5.6 1.6 28.6% Losses not recognised 11.7 4.0 34.5% Total 17.3 5.6 32.4% Summary Revenue FY26 H1 FY25 H1 Change % Reported revenue 102.2 93.6 9% Currency effect (1 & 2) (1.5) Constant currency revenue* 100.7 93.6 8% Summary EBIT FY26 H1 FY25 H1 Change % Reported EBIT 8.4 8.7 -3% Currency effect (1 & 2) (0.6) Currency effect (3) 0.7 (1.3) Constant currency EBIT* 8.5 7.4 15% Summary Profit before tax FY26 H1 FY25 H1 Change % Reported profit before tax 10.6 10.9 -3% Currency effect (1 & 2) (0.5) Currency effect (3) 0.7 (1.3) Constant currency profit before tax* 10.8 9.6 13% For personal use only
Page 31
Nanosonics Limited | FY26 Half Year Results | 31 Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group). While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials. trophon® and CORIS® are registered trade marks of Nanosonics Limited. For personal use only